GlassScriptPhysician profile
Brandon Rodriguez
NPI 1982702759
$83,475.31
in general payments reported to CMS, 2019-2025
21 companies · $886 in 2025
The $886 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $3,004 · 2021: $39K · 2022: $8,666 · 2023: $9,681 · 2024: $2,359 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,799 · Food and Beverage: $2,908 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Travel and Lodging: $902 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,798.55 |
| Food and Beverage | $2,907.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Travel and Lodging | $902.46 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39,137.06 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $10,451.64 | 2020-2025 | Cequa |
| Alcon Vision LLC | $9,342.09 | 2019-2025 | Argos, Ora System Verifeye, Clareon |
| Allergan, INC. | $8,538.17 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $8,103.14 | 2022-2025 | Miebo, Xiidra, Stellaris Elite |
| Eyepoint US, INC. | $6,628.50 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $265.28 | 2020-2025 | Tecnis Iol, Catalys System |
| Glaukos Corporation | $240.40 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Abbvie INC. | $165.18 | 2023-2024 | Xen Glaucoma Treatment System |
| Ocular Therapeutix, INC. | $126.20 | 2019-2024 | Dextenza |
| Oyster Point Pharma, INC. | $110.92 | 2022-2024 | Tyrvaya |
| Shire North American Group INC | $69.05 | 2019 | |
| Kala Pharmaceuticals, INC. | $59.97 | 2021 | |
| Sight Sciences, INC. | $48.08 | 2021-2022 | |
| Amgen INC. | $48.07 | 2025 | Tepezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $30.07 | 2024 | Xdemvy |
| Viiv Healthcare Company | $28.31 | 2025 | |
| Biotissue Holdings INC. | $22.65 | 2025 | |
| Rxsight INC | $22.23 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Novartis Pharmaceuticals Corporation | $19.78 | 2019 | |
| Ivantis, INC | $18.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.